At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Feb 24, 2026 at 17:00 ET
NRx Pharmaceuticals, Inc. filed a supplement to its definitive proxy statement for its 2026 annual meeting, correcting the numbering of proposals on the proxy card and cover letter. The meeting will address director elections, executive compensation, an incentive plan amendment, and auditor ratification. The filing is routine and administrative, with no material financial or strategic changes.
- Filed a supplement to correct proposal numbering on the proxy card and cover letter for the 2026 annual meeting.
- Proposal 2 (executive compensation) was corrected to Proposal 4.
- Proposal 3 (incentive plan amendment) was corrected to Proposal 2.
- Proposal 4 (auditor ratification) was corrected to Proposal 3.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access